Clinical Trials
5 trialsNCT05455619 2026-04-22
Amelia-1
SynDevRx, Inc.
Phase 1/2 Recruiting
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT04330625 2022-11-08
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Duke University
Phase 1 Terminated
NCT05107388 2021-11-04
AAREN
Centre Hospitalier Universitaire de Besancon
Phase NA Unknown